Serum levels and catabolism of 3'-azido-3'-deoxythymidine in vivo measured using a specific radioimmunoassay

Studies on the Reversal of Azidothymidine Toxicity in Human Lymphocytes by Cytidine and Uridine

The toxicity of 3′-azidothymidine (AZT) in human lymphocytes has been shown previously to be reversed by co-incubation with the ribonucleosides cytidine or uridine. In the present paper, the effects of 3′-azidothymidine and cytidine/uridine, both alone and in combination, were studied upon key processes in lymphocytes in order to discover more about the mechanism of toxicity reversal.

In these experiments 3′-azidothymidine had only minor effects on the ribonucleoside triphosphate pools. Cytidine increased the CTP pool, and uridine the UTP pool. Co-incubation with AZT caused similar changes to incubation with cytidine or uridine alone. Toxicity reversal was not linked to replacement of deficient ribonucleoside triphosphate pools.

3′-Azidothymidine caused the excretion of thymidine from lymphocytes. Incubation with cytidine and uridine increased the intracellular cytidine and uridine pools, respectively. Co-incubation with 3′-azidothymidine increased still further the intracellular cytidine and uridine pools. Cytidine and uridine did not affect the intracellular 3′-azidothymidine pool.

The toxicity of 3′-azidothymidine was increased by co-incubation with the bases adenine, guanine, hypoxanthine, and uracil, but not by dihydrouracil, thymine, or xanthine.

Antiretroviral effect of 4-thio-uridylate against human immunodeficiency virus type 1

Antiretroviral effect of thiolated nucleotide 4-thio-uridylate (S4UMP, designated as UD29) against human immunodeficiency virus type 1 (HIV-1) have been quantitatively determined in cell-based viral infectivity assays. In syntitium inhibition assay on MT-2 human T-cell line UD29 prevented cell fusion and formation of syntitia induced by HIV-1IIIB with IC50 values of 11.7 μg/ml. In a single-cycle viral infection assay (MAGI assay) UD29 proved to have a potent inhibitory effect against HIV-1IIIB on HeLaCD4-LTR/β-gal cells, which was dose dependent with IC50 values of 4.75 μg/ml and IC90 of 39.7 μg/ml. UD29 showed a most prominent antiviral effect when administered 30 min prior HIV-1 infection. As HIV entry requires thiol/disulfide exchange process, results suggest that reactive -SH group of enol-form of the thiolated nucleotide may interfere with the function of cell surface proteins. UD29 cannot penetrate into cells and may have an interactive role in redox processes active in viral entry.

Nucleoside reverse transcriptase inhibitor toxicity and mitochondrial DNA

IMPORTANCE OF THE FIELD

HIV/AIDS is a worldwide epidemic. While there remains no cure for the HIV-1 infection, nucleoside reverse transcriptase inhibitors (NRTIs) have helped transform the HIV-1 infection from a lethal disease into a chronic illness. Though NRTIs inhibit HIV-1 replication, they exhibit side effects in human tissues that appear to result from NRTI inhibition of human mitochondrial polymerase γ (pol γ).

AREAS COVERED IN THIS REVIEW

this review discusses the current knowledge of NRTI-induced toxicity, specifically the inhibition of pol γ and the mitochondrial toxicity from incorporation of NRTIs into mitochondrial DNA. Details are discussed about general mechanisms of NRTI toxicity and how specific tissue toxicities in mitochondria relate to clinical manifestation.

WHAT THE READER WILL GAIN

a detailed knowledge of the mitochondrial toxicity resulting from NRTI-inclusive therapies and related tissue toxicities are provided. This review presents both the molecular effects of NRTI usage on mitochondrial genetic homeostasis and energy metabolism as well as the clinical manifestations associated with NRTI toxicities.

TAKE HOME MESSAGE

NRTIs remain a critical component of current HIV-1 treatment regimens. Future NRTIs should provide higher specificity for HIV-RT and lower incorporation by pol γ to minimize mitochondrial toxicity. Alternatively, therapeutic interventions to prevent or alleviate mitochondrial toxicity should be addressed.

[Twenty five years of HIV virus]

At the 25th anniversary of the identification of HIV virus as the causative agent of AIDS, virologist and clinician authors provide an overview of the discovery and identification of HIV, its significance in the development of clinical diagnosis of HIV/AIDS, which led to the development of effective antiretroviral treatment. Besides the epidemiological and sociological aspects of the infection, authors provide a detailed chronology of the special aspects of the fight against HIV/AIDS in Hungary, from the diagnosis of the first HIV and AIDS cases, through the establishment of the nationwide screening network and counseling units to the appearance of drug resistant virus mutants, and the recent penetration of African HIV strains to the country. Further actions are urged locally and worldwide for the better understanding the interactions of the human host organism and the HIV virus for the more effective treatment. For these political consensuses, a large scale long term financial support, views based on scientific and public health evidences, and cooperation of the whole society worldwide are needed.

Sensitive and specific radioimmunoassay for fialuridine: initial assessment of pharmacokinetics after single oral doses to healthy volunteers

Fialuridine (FIAU) is a halogen-substituted analog of thymidine that was undergoing clinical investigation as a drug for the treatment of chronic hepatitis B viral infection. However, clinical trials of FIAU were terminated after adverse events occurred following chronic oral administration. Prior to the termination of clinical trials, a sensitive assay was needed for the measurement of FIAU because of the anticipated low dose administered to patients. We therefore undertook the development of a radioimmunoassay (RIA). A specific antiserum was raised in rabbits following immunization with a 5'-O-hemisuccinate analog of FIAU coupled to keyhole limpet hemocyanin. Radiolabeled FIAU was synthesized by a destannylation procedure by using sodium [125I]iodide. We developed a competitive-binding procedure and used precipitation with polyethylene glycol as the method for separating the bound and free forms of FIAU. The RIA is sensitive (0.2 ng/ml), specific (negligible interference from known metabolites and endogenous nucleosides), and reproducible (interassay coefficients of variation range from 5 to 19.7% for serum controls). We used the RIA to assess the pharmacokinetics of FIAU in healthy adult volunteers following administration of a single 5-mg oral dose. The sensitivity of the RIA permitted the detection of a prolonged elimination phase for FIAU in healthy volunteers and dogs, with mean elimination half-lives of 29.3 and 35.3 h, respectively. We conclude the RIA is a valid method for the quantification of FIAU in biological fluids.

Quantification of zidovudine and one of its metabolites in plasma and urine by solid-phase extraction and high-performance liquid chromatography

A rapid, sensitive and selective method for the quantification of zidovudine (AZT) and one of its metabolites (the 5'-glucuronyl form of zidovudine, G-AZT) in biological fluids is described, based on high-performance liquid chromatography. Solid-phase extraction on-line with chromatographic separation was used. The limit of quantitation of the assay is 10 ng/ml of plasma or urine for G-AZT and 20 ng/ml of plasma or urine for AZT.